September 2026, Tangerang, Indonesia — The three-day 2026 Indonesia International Pet Expo (IIPE 2026) concluded successfully on September 4–6 at ICE BSD City. As Indonesia's most influential annual pet industry event, this year's edition marked the 10th anniversary of IIPE and was held under the theme "Unleash The Energy," bringing together 295 exhibitors from around the world along with tens of thousands of trade visitors and pet enthusiasts.

Our company showcased multiple core pharmaceutical products at the expo, generating strong on-site interest. Following the event, our team made dedicated visits to local client animal hospitals to hold substantive discussions on deeper cooperation, marking a key step forward in our commitment to the Indonesian market.

On-Site at the Expo: Pharmaceutical Products Draw Strong Interest from Trade Visitors

This year's IIPE set a new record in scale. According to figures released by the organizer, the three-day event recorded 78,758 visitors, with exhibitors spanning pet food, grooming supplies, animal health, and technology, among other sectors. In the animal health products section, our booth attracted a steady stream of trade buyers, drawn by our pharmaceutical solutions targeting common pet diseases and post-operative recovery.

Unlike booths showcasing pet food and supplies for general consumers, our pharmaceutical booth welcomed primarily professional visitors — local pet clinic owners, veterinarians, dealers, and distributors. Numerous visitors inquired in detail about product ingredients, indications, and clinical feedback, and held preliminary discussions on registration procedures, supply cycles, and regional agency terms. After learning about the proven applications of our products in animal hospital settings, several clients expressed a clear interest in receiving further product documentation.

During the expo, our team also observed that Indonesia's veterinary pharmaceutical market is in a phase of rapid growth. With pet ownership continuing to rise and pet owners becoming more health-conscious, animal hospitals and clinics face increasingly urgent demand for high-quality medicines and medical solutions. This trend presents a favorable window for our pharmaceutical products to enter the Indonesian market.

Post-Show Visits: In-Depth Discussions at Animal Hospitals to Advance Cooperation

The day after the expo closed, our team proceeded as scheduled to visit several prospective client animal hospitals in Jakarta and surrounding areas. The core objective of these visits was to translate the initial contacts established during the expo into concrete cooperation frameworks.

At the client animal hospitals, our team conducted on-site assessments of the clinical environment, medication practices, and inventory management processes, and held discussions with hospital directors and attending veterinarians. The hospitals provided detailed briefings on the local disease spectrum, existing pharmaceutical supply chain structures, and pain points in clinical practice. Our team presented information on product storage requirements, dosage guidance, technical support, and after-sales response mechanisms. Both sides exchanged views on substantive topics including product category priorities for introduction, initial order volumes, pricing terms, and follow-up training support.

Some clients confirmed sample requests on the spot and indicated their willingness to initiate procurement procedures after completing internal evaluations. Others requested clinical data on specific indications to support recommendations to their partner clinic networks. These face-to-face discussions effectively addressed the limitations of the expo setting — where time was limited and exchanges could not go deep enough — and laid a foundation of trust for subsequent contract signing.

Market Outlook: Entering Indonesia's Veterinary Ecosystem Through Pharmaceuticals

Didit Siswodwiatmoko, founder of IIPE organizer PT Temali Indonesia, noted during the expo that Indonesia's pet industry is transitioning from a "basic development phase" to a "quality-driven growth phase," with industry players shifting their focus from pure product sales toward deeper dimensions such as professional capability, clinical outcomes, and animal welfare. This assessment aligns closely with the client feedback we gathered during our visits.

This expo participation and client visitation have further clarified our positioning in the Indonesian market: to use pharmaceutical products as a core entry point, build long-term partnerships with local animal hospitals and professional distributors, and gradually construct a service chain spanning from product supply to clinical support. Indonesia's veterinary pharmaceutical market is still at a stage where no brand landscape has been firmly established, and the clinical end shows relatively high acceptance of imported high-quality medicines — presenting a rare opportunity for companies with product strength and technical service capabilities.

Next, based on the feedback collected from the expo and client visits, our company will accelerate registration preparation and sample shipments for target products, while maintaining regular follow-up with key clients. Our expansion into the Indonesian market is now moving from the "showcase" stage into the "implementation" stage.